Efficacy and Safety of Alirocumab as Add-on Therapy in High-Cardiovascular-Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies

Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia

(2014) Jennifer G. Robinson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

(2013) Todd J. Anderson et al.   CANADIAN JOURNAL OF CARDIOLOGY

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   CIRCULATION

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia

(2013) Scott M. Grundy   Journal of Clinical Lipidology

Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease

(2013) Peter P. Toth et al.   Journal of Clinical Lipidology

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin‐Treated Subjects From 3 Data Sources: A Retrospective Analysis

(2013) Peter H. Jones et al.   Journal of the American Heart Association

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)

(2012) Joep Perk et al.   ATHEROSCLEROSIS

Heart Disease and Stroke Statistics—2013 Update

(2012) Alan S. Go et al.   CIRCULATION

Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein lowering

(2012) Allan Sniderman et al.   Journal of Clinical Lipidology

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

(2012) James M. McKenney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

(2012) Eli M. Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study

(2011) J. R. Banegas et al.   EUROPEAN HEART JOURNAL

Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey

(2011) Jeong Euy Park et al.   European Journal of Preventive Cardiology

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands

(2009) A.H. Pijlman et al.   ATHEROSCLEROSIS

Lipid Treatment Assessment Project 2

(2009) David D. Waters et al.   CIRCULATION

MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets

(2009) Ohidul Siddiqui et al.   Journal of Biopharmaceutical Statistics

Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries

(2009) Kornelia Kotseva et al.   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE